QSC Tirzepatide 2mg-30mg LY3298176 GIP/GLP-1 RA Lyophilized Powder for Research

QSC Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This white lyophilized powder demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The QSC tirzepatide formulation shows particular affinity for GIP receptors while maintaining significant GLP-1 receptor activity. This dual mechanism has been shown to produce enhanced reductions in hyperglycemia in research settings. The compound mimics natural GIP action at GIP receptors while providing the beneficial effects of GLP-1 receptor activation.

Our facility offers QSC tirzepatide in various concentrations and packaging options to meet diverse research requirements. Custom formulations from 2mg to 50mg are available, with vial packaging options including 5mg/vial, 10mg/vial, 15mg/vial, 20mg/vial, and 30mg/vial configurations.

The product undergoes rigorous quality control testing to ensure 99% purity and meets pharmaceutical grade standards. Third-party laboratory verification is available to confirm product specifications and performance characteristics.

For research purposes only. Not for human consumption. Proper laboratory handling procedures should be followed when working with this compound.